Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"HRA Pharma","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2,100.0 million","newsHeadline":"Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Esteve Healthcare","pharmaFlowCategory":"D","amount":"$294.2 million","upfrontCash":"$203.3 million","newsHeadline":"Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to \u20ac275 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by HRA Pharma

    Menu

    HRA Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              HRA Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million

              Details:

              Through the divestment, Esteve expand its rare disease business portfolio, by including Metopirone (metyrapone), can be used to treat the signs and symptoms of Cushing's syndrome by lowering high levels of cortisol a hormone produced by the adrenal glands.

              Lead Product(s): Metyrapone

              Therapeutic Area: Endocrinology Product Name: Metopirone

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Esteve Healthcare

              Deal Size: $294.2 million Upfront Cash: $203.3 million

              Deal Type: Divestment April 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HRA Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma

              Details:

              HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®).

              Lead Product(s): Ulipristal Acetate

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ellaOne

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Perrigo Company plc

              Deal Size: Undisclosed Upfront Cash: $2,100.0 million

              Deal Type: Acquisition September 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY